Jun Wang, PhD

Associate Professor, Department of Pathology, NYU Grossman School of Medicine / NYU Langone Health

Dr. Jun Wang is an Associate Professor of Pathology at NYU Grossman School of Medicine. He earned a Ph.D. in Molecular Immunology from the Chinese Academy of Sciences, where he investigated the mechanisms underlying liver toxicity associated with anti-4-1BB immunotherapy. He subsequently completed postdoctoral training in cancer immunotherapy at Yale University.
Dr. Wang has over two decades of experience in immunotherapy, with a focus on immune checkpoint biology, the discovery of novel immune receptor–ligand pathways, and their translation into therapies for cancer and autoimmune diseases. He is among the first to characterize multiple immune regulatory mechanisms, including FGL1/LAG-3, Siglec-15, MHC-I membrane inhibitors, SARS-CoV-2 myeloid receptors, LAG-3–based bispecific T-cell silencers, and myeloid immune feedback modulators, establishing new paradigms for immune regulation and therapeutic intervention.

Dr. Wang is the founder and scientific advisor of Remunix Inc. and Feedback Tx, a founding scientist of NextCure Inc. (NASDAQ: NXTC), and co-founder of non-profit organization BioSpark Group. He also serves as a scientific advisory board member/advisor for Henlius, Hanmi, LAV, and Regeneron. His contributions have been recognized with several honors, including the V Scholar Award, the Melanoma Research Alliance Young Investigator Award, the Mark Foundation ASPIRE Award, the Colton Center for Autoimmunity Research Award, and the ACACR Tony Hunter Award.